Conditions: Diabetes Mellitus Non-insulin-dependent
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 10
Healthy volunteers: no

Brief summary:
to assess the effect of treatment with Sitagliptin (MK0431) on HbA1c (Hemoglobin A1c) and the safety and tolerability of Sitagliptin.

Detailed description:

Arms:
arm 1: sitagliptin

Interventions: intervention 1: sitagliptin
Intervention descriptions: intervention 1: Sitagliptin, 100 mg, 1 Tablet, once a day, for 18 weeks

Protocol document: